Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tibor Bakacs

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Cureus|January 13, 2022
Healing of Severe Herpes Zoster Ophthalmicus Within a Few Days: An Autobiographical Case ReportTibor Bakacs
Infectious Disorders Drug Targets|April 6, 2019
Therapeutic Exploitation of Viral InterferenceImre Kovesdi, Tibor Bakacs
Frontiers in Immunology|March 13, 2026
Host-targeted oral avian vaccine virus demonstrates broad antiviral activity and safety in patientsTibor Bakacs, Konstantin Chumakov
Immunobiology|February 2, 2015
Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiencyTibor Bakacs, Jitendra N Mehrishi
Scandinavian Journal of Immunology|March 11, 2026
Rethinking Immune Checkpoint Inhibition in CancerTibor Bakacs, Colin C Anderson
Cureus|September 30, 2022
An Orally Administered Nonpathogenic Attenuated Vaccine Virus Can Be Used to Control SARS-CoV-2 Infection: A Complementary Plan B to COVID-19 VaccinationTibor Bakacs, Volker Sandig, Imre Kovesdi
Hepatology, Medicine and Policy|October 6, 2018
Post-infection viral superinfection technology could treat HBV and HCV patients with unmet needsTibor Bakacs, Rifaat Safadi, Imre Kovesdi
Pharmaceuticals (Basel, Switzerland)|June 1, 2023
Combination Therapy for the Treatment of Shingles with an Immunostimulatory Vaccine Virus and AcyclovirTibor Bakacs, Volker Sandig, Imre Kovesdi
Pharmacological Research|November 9, 2013
Control of minimal residual cancer by low dose ipilimumab activating autologous anti-tumor immunityShimon Slavin, Ralph W Moss, Tibor Bakacs
Immunobiology|August 9, 2011
Ipilimumab (Yervoy) and the TGN1412 catastropheTibor Bakacs, Jitendra N Mehrishi, Ralph W Moss
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Cureus|January 13, 2022
Healing of Severe Herpes Zoster Ophthalmicus Within a Few Days: An Autobiographical Case ReportTibor Bakacs
Infectious Disorders Drug Targets|April 6, 2019
Therapeutic Exploitation of Viral InterferenceImre Kovesdi, Tibor Bakacs
Frontiers in Immunology|March 13, 2026
Host-targeted oral avian vaccine virus demonstrates broad antiviral activity and safety in patientsTibor Bakacs, Konstantin Chumakov
Immunobiology|February 2, 2015
Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiencyTibor Bakacs, Jitendra N Mehrishi
Scandinavian Journal of Immunology|March 11, 2026
Rethinking Immune Checkpoint Inhibition in CancerTibor Bakacs, Colin C Anderson
Cureus|September 30, 2022
An Orally Administered Nonpathogenic Attenuated Vaccine Virus Can Be Used to Control SARS-CoV-2 Infection: A Complementary Plan B to COVID-19 VaccinationTibor Bakacs, Volker Sandig, Imre Kovesdi
Hepatology, Medicine and Policy|October 6, 2018
Post-infection viral superinfection technology could treat HBV and HCV patients with unmet needsTibor Bakacs, Rifaat Safadi, Imre Kovesdi
Pharmaceuticals (Basel, Switzerland)|June 1, 2023
Combination Therapy for the Treatment of Shingles with an Immunostimulatory Vaccine Virus and AcyclovirTibor Bakacs, Volker Sandig, Imre Kovesdi
Pharmacological Research|November 9, 2013
Control of minimal residual cancer by low dose ipilimumab activating autologous anti-tumor immunityShimon Slavin, Ralph W Moss, Tibor Bakacs
Immunobiology|August 9, 2011
Ipilimumab (Yervoy) and the TGN1412 catastropheTibor Bakacs, Jitendra N Mehrishi, Ralph W Moss
Pageof 2